Palatin Technologies rises on higher prelim product revenue for Vyleesi

Palatin Technologies

19/04/2023 17:57

** Shares of biopharmaceutical company Palatin Technologies
Inc  PTN.A  up 3.7% at $2.75 in the afternoon trade
    ** Co's Q3 prelim net product revenue for Vyleesi surged
more than five fold to $1.2 mln from comparable quarter in 2022
    ** Vyleesi is a prescription medicine used for treat
hypoactive sexual desire disorder (HSDD) in pre-menopausal women
    ** Co says it is actively seeking Vyleesi collaborations for
the United States and for territories outside the currently
licensed territories of China and Korea
    ** Including session's gains, stock up 7.42% YTD 

 (Reporting By Akshita Toshniwal)
 ((Akshita.Toshniwal@thomsonreuters.com))